These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36517634)

  • 41. Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study.
    Maughan BL; Luber B; Nadal R; Antonarakis ES
    Prostate; 2017 Jan; 77(1):33-40. PubMed ID: 27527643
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
    Zhang T; Dhawan MS; Healy P; George DJ; Harrison MR; Oldan J; Chin B; Armstrong AJ
    Clin Genitourin Cancer; 2015 Aug; 13(4):392-399. PubMed ID: 25708161
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
    Khalaf DJ; Aragón IM; Annala M; Lozano R; Taavitsainen S; Lorente D; Finch DL; Romero-Laorden N; Vergidis J; Cendón Y; Oja C; Pacheco MI; Zulfiqar M; ; Gleave ME; Wyatt AW; Olmos D; Chi KN; Castro E
    Ann Oncol; 2020 Sep; 31(9):1186-1197. PubMed ID: 32574722
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting.
    Jung SI; Kim MS; Jeong CW; Kwak C; Hong SK; Kang SH; Joung JY; Lee SH; Yun SJ; Kim TH; Park SW; Jeon SS; Kang M; Lee JY; Chung BH; Hong JH; Ahn H; Kim CS; Kwon DD
    Investig Clin Urol; 2020 Jan; 61(1):19-27. PubMed ID: 31942459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Govindan S; Cheranda N; Riekhof F; Luo S; Schoen MW
    Prostate; 2024 Feb; 84(3):245-253. PubMed ID: 37909677
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
    Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
    Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide.
    Buttigliero C; Tucci M; Sonetto C; Vignani F; Di Stefano RF; Pisano C; Turco F; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
    Minerva Urol Nefrol; 2020 Dec; 72(6):737-745. PubMed ID: 32284527
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
    Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
    Clin Genitourin Cancer; 2018 Apr; 16(2):142-148. PubMed ID: 29042308
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
    Stangl A; Wilner C; Li P; Maahs L; Hwang C; Pilling A
    Prostate; 2023 May; 83(6):524-533. PubMed ID: 36604824
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
    Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
    Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
    BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis.
    Shimomura T; Mori K; Yasue K; Matsukawa A; Fukuokaya W; Yanagisawa T; Hata K; Murakami M; Koike Y; Miki J; Yamada H; Kimura T
    Int J Clin Oncol; 2024 Feb; 29(2):213-221. PubMed ID: 38103156
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
    George DJ; Halabi S; Heath EI; Sartor AO; Sonpavde GP; Das D; Bitting RL; Berry W; Healy P; Anand M; Winters C; Riggan C; Kephart J; Wilder R; Shobe K; Rasmussen J; Milowsky MI; Fleming MT; Bearden J; Goodman M; Zhang T; Harrison MR; McNamara M; Zhang D; LaCroix BL; Kittles RA; Patierno BM; Sibley AB; Patierno SR; Owzar K; Hyslop T; Freedman JA; Armstrong AJ
    Cancer; 2021 Aug; 127(16):2954-2965. PubMed ID: 33951180
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.
    Hafron JM; Wilfehrt HM; Ferro C; Harmon M; Flanders SC; McKay RR
    Adv Ther; 2022 Jun; 39(6):2515-2532. PubMed ID: 35352309
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide.
    Poteska R; Rahbar K; Semjonow A; Schrader AJ; Boegemann M; Schlack K
    BMC Cancer; 2022 Apr; 22(1):375. PubMed ID: 35395766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
    Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
    Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
    Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.
    Siemens DR; Klotz L; Heidenreich A; Chowdhury S; Villers A; Baron B; van Os S; Hasabou N; Wang F; Lin P; Shore ND
    J Urol; 2018 Jan; 199(1):147-154. PubMed ID: 28827103
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
    Pezaro CJ; Omlin AG; Altavilla A; Lorente D; Ferraldeschi R; Bianchini D; Dearnaley D; Parker C; de Bono JS; Attard G
    Eur Urol; 2014 Sep; 66(3):459-65. PubMed ID: 24411987
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enzalutamide Treatment in Metastatic Castration-resistant Prostate Cancer: Before and after Docetaxel.
    Bilgetekin I; Basal FB; Cinkir HY; Esin E; Oksuzoglu B; Demirci U
    J Coll Physicians Surg Pak; 2020 Aug; 30(8):815-821. PubMed ID: 32893792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.